SG11201506093SA - N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals - Google Patents

N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals

Info

Publication number
SG11201506093SA
SG11201506093SA SG11201506093SA SG11201506093SA SG11201506093SA SG 11201506093S A SG11201506093S A SG 11201506093SA SG 11201506093S A SG11201506093S A SG 11201506093SA SG 11201506093S A SG11201506093S A SG 11201506093SA SG 11201506093S A SG11201506093S A SG 11201506093SA
Authority
SG
Singapore
Prior art keywords
azaindazol
sulfonamides
pharmaceuticals
phenyl
Prior art date
Application number
SG11201506093SA
Inventor
Marc Nazaré
Nis Halland
Friedemann Schmidt
Heinz-Werner Kleemann
Tilo Weiss
Joachim Saas
Carsten Struebing
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG11201506093SA publication Critical patent/SG11201506093SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201506093SA 2013-03-13 2014-03-12 N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals SG11201506093SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13305283 2013-03-13
PCT/EP2014/054770 WO2014140065A1 (en) 2013-03-13 2014-03-12 N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
SG11201506093SA true SG11201506093SA (en) 2015-09-29

Family

ID=48040124

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201506093SA SG11201506093SA (en) 2013-03-13 2014-03-12 N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals

Country Status (24)

Country Link
US (1) US9718825B2 (en)
EP (1) EP2970259B1 (en)
JP (1) JP6404241B2 (en)
KR (2) KR102219160B1 (en)
CN (1) CN105189502B (en)
AR (1) AR095279A1 (en)
AU (1) AU2014230805B2 (en)
BR (1) BR112015020287B1 (en)
CA (2) CA3111517A1 (en)
CY (1) CY1119151T1 (en)
DK (1) DK2970259T3 (en)
ES (1) ES2618213T3 (en)
HR (1) HRP20170337T1 (en)
HU (1) HUE031540T2 (en)
IL (1) IL240178A (en)
LT (1) LT2970259T (en)
MX (1) MX363658B (en)
PL (1) PL2970259T3 (en)
PT (1) PT2970259T (en)
RU (1) RU2671864C2 (en)
SG (1) SG11201506093SA (en)
SI (1) SI2970259T1 (en)
TW (1) TWI629275B (en)
WO (1) WO2014140065A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3325100A4 (en) 2015-07-17 2019-02-20 Memorial Sloan-Kettering Cancer Center Combination therapy using pdk1 and pi3k inhibitors
JOP20190053A1 (en) 2016-09-23 2019-03-21 Novartis Ag Aza-indazole compounds for use in tendon and/or ligament injuries
TWI651308B (en) * 2016-09-23 2019-02-21 瑞士商諾華公司 Carbazole compound for tendon and/or ligament injury
US11236083B2 (en) 2016-12-07 2022-02-01 Orimos Therapeutics Co., Ltd. Compounds and pharmaceutical compositions for modulating SGK activity, and methods thereof
TWI782056B (en) * 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 A fused ring derivative having a mgat2 inhibitoy activity
KR20200036004A (en) * 2017-08-01 2020-04-06 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
WO2020060268A1 (en) 2018-09-20 2020-03-26 한미약품 주식회사 Novel sulfonamide derivative with fused pyrimidine skeleton, having epidermal growth factor receptor mutation inhibitory effect
CN113498352A (en) 2019-01-23 2021-10-12 施万生物制药研发Ip有限责任公司 Imidazo [1,5-A ] pyridines, 1,2, 4-triazolo [4,3-A ] pyridines and imidazo [1,5-A ] pyrazines as JAK inhibitors
WO2020178316A1 (en) * 2019-03-05 2020-09-10 Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.P.A. 5- or 7-azaindazoles as beta-lactamase inhibitors
US20220388964A1 (en) * 2019-04-12 2022-12-08 Hibercell, Inc. (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions
CN110379468B (en) * 2019-07-17 2022-08-23 成都火石创造科技有限公司 Improved chemical molecular formula segmentation method
JP2024502178A (en) * 2021-01-13 2024-01-17 スリブ セラピューティクス インコーポレイテッド Pyrazolo[3,4-D]pyrimidin-6-yl-sulfonamide derivatives for inhibiting SGK-1
EP4147700A1 (en) 2021-09-08 2023-03-15 LQT Therapeutics Inc. N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides for use in the treatment of sickle cell disease
WO2024011316A1 (en) * 2022-07-12 2024-01-18 Thryv Therapeutics Inc. Salts of n-[4-(4-[[2-(dimethylamino)ethyl]amino]-3-methyl-1h-pyrazolo[3,4-d]pyrimidin-6-yl)-2-fluorophenyl]-2,5-difluorobenzenesulfonamide and crystalline forms thereof
WO2024015055A1 (en) * 2022-07-13 2024-01-18 Thryv Therapeutics Inc. Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1 and treatment of cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2824121A (en) 1954-11-04 1958-02-18 Kay Fries Chemicals Inc Process for preparation of oxy alkylidene compounds
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
ES2309206T3 (en) * 2001-10-02 2008-12-16 Smithkline Beecham Corporation CHEMICAL COMPOUNDS.
US7405220B2 (en) 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
DE102004059781A1 (en) 2004-12-10 2006-06-22 Sanofi-Aventis Deutschland Gmbh Use of serum / glucocorticoid-regulated kinase
PE20061119A1 (en) * 2005-01-19 2006-11-27 Aventis Pharma Sa PYRAZOLO PYRIDINES SUBSTITUTED AS INHIBITORS OF FAK, KDR AND Tie KINASES
FR2889526B1 (en) * 2005-08-04 2012-02-17 Aventis Pharma Sa SUBSTITUTED 7-AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PROCESS FOR PRODUCTION AND USE
GB0606804D0 (en) * 2006-04-04 2006-05-17 Novartis Ag Organic Compounds
CA2664375A1 (en) * 2006-09-28 2008-04-03 Novartis Ag Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use
DE102007002717A1 (en) * 2007-01-18 2008-07-24 Merck Patent Gmbh Heterocyclic indazole derivatives
US20080234262A1 (en) 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
WO2010118367A2 (en) * 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
EP2789615B1 (en) * 2009-08-11 2017-05-03 Bristol-Myers Squibb Company Azaindazoles as Btk kinase modulators and use thereof
AU2011377409B2 (en) * 2011-09-19 2017-05-25 Sanofi N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals
JP5827849B2 (en) * 2011-09-20 2015-12-02 サノフイ N- [4- (1H-pyrazolo [3,4-b] pyrazin-6-yl) -phenyl] -sulfonamide and its use as a medicament

Also Published As

Publication number Publication date
BR112015020287A2 (en) 2017-07-18
US20160024097A1 (en) 2016-01-28
CA2901534C (en) 2021-04-27
CA2901534A1 (en) 2014-09-18
IL240178A (en) 2016-08-31
AR095279A1 (en) 2015-09-30
CN105189502A (en) 2015-12-23
CA3111517A1 (en) 2014-09-18
BR112015020287B1 (en) 2022-12-13
TW201512194A (en) 2015-04-01
MX2015011353A (en) 2015-12-16
US9718825B2 (en) 2017-08-01
TWI629275B (en) 2018-07-11
RU2671864C2 (en) 2018-11-07
JP6404241B2 (en) 2018-10-10
AU2014230805B2 (en) 2018-02-15
KR20210021127A (en) 2021-02-24
EP2970259A1 (en) 2016-01-20
RU2015143000A (en) 2017-04-20
HRP20170337T1 (en) 2017-04-21
WO2014140065A1 (en) 2014-09-18
JP2016514116A (en) 2016-05-19
SI2970259T1 (en) 2017-05-31
CY1119151T1 (en) 2018-02-14
LT2970259T (en) 2017-03-27
EP2970259B1 (en) 2016-12-21
PT2970259T (en) 2017-03-10
KR20150130443A (en) 2015-11-23
HUE031540T2 (en) 2017-07-28
KR102219160B1 (en) 2021-02-23
AU2014230805A1 (en) 2015-09-24
IL240178A0 (en) 2015-09-24
ES2618213T3 (en) 2017-06-21
PL2970259T3 (en) 2017-06-30
DK2970259T3 (en) 2017-03-20
CN105189502B (en) 2017-05-31
MX363658B (en) 2019-03-28

Similar Documents

Publication Publication Date Title
SG11201506093SA (en) N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
HK1223975A1 (en) Nanobubble-containing composition and use thereof
HK1203493A1 (en) Substituted azabicycles and use thereof
HRP20160796T1 (en) Bicyclically substituted uracils and the use thereof
EP3006431A4 (en) Tizoxanide carbamate and pharmaceutical use thereof
HK1203198A1 (en) Substituted phenylimidazopyrazoles and use thereof
HK1207301A1 (en) Substituted benzamides and their uses
BR112014020372A8 (en) n-ethyl-n-phenyl-1,2-dihydro-4,5-dihydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and use thereof
ZA201503797B (en) Substituted biaryl sulfonamides and the use thereof
EP3043790A4 (en) Novel anthranilic amides and the use thereof
GB201301979D0 (en) New composition and use thereof
HK1223307A1 (en) Novel compounds and uses thereof
IL240177A (en) Substituted chroman-6-yloxy-cycloalkanes and their use as pharmaceuticals
SI3024825T1 (en) Imidazolecarboxamides and their use as faah inhibitors
IL240447A (en) Biaryl-propionic acid derivatives and their use as pharmaceuticals
IL240422A0 (en) Biaryl-propionic acid derivatives and their use as pharmaceuticals
GB201313605D0 (en) Novel compounds and their use
EP3050893A4 (en) Glycoamino acid and use thereof
GB201309328D0 (en) Product and use thereof